Defucosylated anti-C-C chemokine receptor 4 (CCR4) IgG1 has been approved by the US Food and Drug Administration (FDA) for the treatment of relapsed or refractory mycosis fungoides or Sézary syndrome 23,24. The gene discussed is CCR4; the disease is mycosis fungoides.